TILT Q2 2025 revenue falls 45% to $10.5M, net loss narrows to $9.2M

TILT Holdings Inc.

2025-Q2 EPS reported -$0.05 revenue$27,417,000

Revenue from continuing operations $10.5M, down from $19.0M YoY; gross margin 17.4% vs 18.9%.
Net loss from continuing operations $9.2M, improved from $16.6M loss in Q2 2024.
Adjusted EBITDA from continuing operations -$2.0M vs -$1.2M in prior year.
Received MA CCC approval for dispensary sale to In Good Health; closing expected Q3.
EU MDR certification for QMID vaporizer; partnered with Curaleaf International for global medical markets.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.